Pediatric pulmonary arterial hypertension is a progressive vasculopathy with substantial early mortality. Subcutaneous treprostinil is an established prostacyclin-pathway therapy for higher-risk disease, but long-term pediatric data from Latin American referral centers remain limited.
Pulmonary hypertension (PH) is a severe complication of Takayasu arteritis (TAK) with pulmonary artery involvement (PAI), associated with poor prognosis. Serum uric acid (UA) has been linked to both TAK severity and PH in other settings, but its role specifically in TAK-PAI-associated PH remains unclear.
Chronic thromboembolic pulmonary hypertension (CTEPH) is a distinct subtype of pulmonary hypertension arising from persistent major pulmonary artery obstruction after pulmonary embolism.
Tricuspid annular plane systolic excursion (TAPSE) is primarily measured using motion-mode (M-mode) echocardiography. However, image resolution doesn't always provide clear visualization. In these cases, tissue Doppler imaging (TDI) may offer a valuable alternative for right ventricular assessment.
Splenic focused ultrasound (sFUS) neuromodulation improves monocrotaline-induced pulmonary hypertension in rats of both sexes, with females achieving near-normalization of right ventricular systolic pressure and males showing partial improvement.
Assessment of right atrial (RA) structure helps monitor right heart (RH) function, critical for prognosis in pulmonary arterial hypertension (PAH). This study aims to assess the prognostic value of RA adverse remodeling (RAAR) with targeted therapy in PAH.
Pulmonary hypertension (PH) is a progressive disease associated with high morbidity and mortality. Despite advancements, gaps in PH care quality persist, though the drivers of these gaps are incompletely understood.
Pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) are life-threatening forms of pulmonary hypertension (PH) that require early recognition and referral to expert centers.
Pulmonary hypertension (PH) is a common complication of interstitial lung disease (ILD), yet data on screening in heterogenous ILD populations are limited. We evaluated whether routinely measured pulmonary function test (PFT) parameters identify individuals with intermediate-to-high echocardiographic risk of PH.
